key: cord-0895666-s00m5xhk authors: Blackett, John W.; Wainberg, Milton; Elkind, Mitchell S.V.; Freedberg, Daniel E. title: Potential long COVID-19 gastrointestinal symptoms 6 months after coronavirus infection are associated with mental health symptoms date: 2021-10-30 journal: Gastroenterology DOI: 10.1053/j.gastro.2021.10.040 sha: db76a9049897f7c1335759b469cec9d260cb4a6b doc_id: 895666 cord_uid: s00m5xhk nan Over 200 million people globally have been infected with the SARS-CoV-2 virus. 1 Some COVID-19 survivors recover from acute infection yet suffer from persistent symptoms including fatigue, anxiety, and depression. 2 New, chronic gastrointestinal (GI) symptoms are also commonly reported after COVID-19. [3] [4] [5] [6] [7] There is an established association between mental health symptoms and chronic GI symptoms, especially irritable bowel syndrome. 8, 9 However, the association between mental health symptoms and chronic GI symptoms after COVID-19 has not been fully explored. This survey study, nested within a prospective cohort of COVID-19 survivors with a minimum of 6 months of follow-up time, assessed the hypothesis that mental health symptoms both preceding and following COVID-19 infection would be associated with post-COVID chronic GI symptoms (see Methods Supplement for full study details). Of 1,783 patients surveyed, 749 (42%) responded (67% female, median age 43). The cohort was 61% white, 9.6% Black, and 20% other races, with 9.6% choosing not to answer; it was 28% Hispanic and 70% non-Hispanic, with 2% choosing not to answer. 93% of the respondents completed the survey in English, and 6.8% in Spanish. 15% of the patients had been hospitalized for COVID, with 1.7% requiring mechanical ventilation. Six months after COVID diagnosis, 220 patients (29%) reported GI symptoms self-perceived to be COVID-related. These included 72 (9.6%) with diarrhea, 83 (11%) with constipation, 70 (9.4%) with abdominal pain, 53 (7.1%) with nausea/vomiting, and 122 (16%) with heartburn ( Table 1) . A GI symptom was the most bothersome current symptom in 83 patients (11%). Thirty-nine patients (5.2%) reported pre-COVID mental health symptoms (which were not further classified in the survey), and 280 (37%) reported post-COVID mental health symptoms (27% with sadness, 34% with anxiety). Patients with pre-COVID mental health symptoms were more likely than those without to report GI symptoms post-COVID (49% vs. 28% respectively, p=0.01, Table Neither Black race nor Hispanic ethnicity was associated with GI symptoms after COVID-19, although preference for the Spanish language was (aOR 2.55, 95% CI 1.14 to 5.73). This discrepancy may represent subtle differences in translation or unmeasured factors-such as access to care, socioeconomic status, or strength of social networks-which fundamentally differ between Hispanics who do or do not prefer Spanish. Of 33 patients with abdominal pain that started after COVID-19 who answered additional questions pertaining to irritable bowel syndrome (IBS), 13 (39%) reported having pain at least weekly that was associated with a change in stool form or frequency, with onset at least 6 months prior, and thus met Rome IV criteria for IBS. Women were no more likely than men to report post-COVID GI symptoms (p=0.63) or to meet criteria for IBS (p=0.56). Of 110 patients hospitalized with COVID-19, 51% reported post-COVID GI symptoms, compared to 26% of non-hospitalized patients (p<0.01). This association remained significant on multivariable analysis (aOR 2.30, 95% CI 1.38-3.84), suggesting that more severe infection may be an important risk factor for post-COVID GI symptoms. Overall, these results highlight the potential bidirectionality of mental health and and chronic GI symptoms after COVID-19, as has previously been observed in non-COVID studies. Anxiety or sadness may exacerbate functional GI symptoms, and functional GI symptoms may lead to anxiety or sadness. 10 Alternatively, a common underlying mechanism could explain both GI and mental health symptoms. This study, which involved an assessment made at a single time point, cannot fully determine the temporality between mental health and GI symptoms after COVID-19. This may be a fruitful area for future studies which can use longitudinal assessment strategies to tease apart the causal chain of events and evaluate strategies to improve long-term GI outcomes after COVID-19. While all patients with chronic GI symptoms should receive screening for co-morbid mental health symptoms, this study provides specific evidence that screening COVID-19 survivors will be high yield. The study has some limitations. The response rate was 42%, raising the possibility of response bias but, reassuringly, the estimate of prevalence for new GI symptoms after COVID-19 (29%) fell squarely in the middle of the range of 16 to 40% from a prior retrospective study. 7 While post-COVID symptoms were assessed prospectively, reporting of mental health symptoms before COVID was assessed retrospectively and may have been under-reported due to recall bias related to the stigma of such symptoms. Because the survey instrument from which these data were generated was focused primarily on new physical symptoms after COVID-19, there was limited detail on the characteristics of current mental health symptoms. Importantly, the association found between mental health symptoms and GI symptoms after COVID-19 is not necessarily causal. It is possible that post-COVID GI symptoms may be partially due to heightened stress and anxiety arising from pandemic-related lifestyle changes, rather than the direct consequence of SARS-CoV-2 infection. In future studies, a control group assessing the incidence of new GI symptoms in patients who tested negative for COVID would help to clarify this question. In sum, we observed very strong associations between mental health symptoms and post-COVID GI symptoms. Nearly a third of patients (29%) reported at least one new GI symptom after COVID-19. These were not trivial, as over 10% of the cohort reported a GI symptom as their most bothersome COVID-related condition. This was a prospective, nested case-control study among 1,783 patients diagnosed with COVID-19 at a single center in New York City. Patients with a positive SARS-CoV-2 polymerase chain reaction test at Columbia University Irving Medical Center who survived and consented to follow up were prospectively enrolled in a COVID-19 cohort from April to November 2020. Six months after their diagnosis, they received an electronic survey regarding ongoing self-perceived COVIDrelated symptoms and pre-COVID mental health symptoms. Specifically, they were asked whether they experienced emotional, mental health, or psychosocial symptoms before they were diagnosed with COVID. For all current symptoms, they were asked about the presence, severity (very mild, mild, moderate, severe, or very severe), and frequency (occasionally, sometimes, often, always) of a wide range of symptoms. The current gastrointestinal symptoms queried in the survey were abdominal pain, nausea/vomiting, heartburn/reflux, diarrhea, or constipation. The current mental health symptoms were sadness and anxiety. For patients who experienced abdominal pain, they were also asked whether the pain occurred at least weekly, whether it was associated with a change in stool form or stool frequency, whether it started after COVID, and whether it had been present at least 6 months. Demographic factors including age, sex, race, ethnicity, and clinical information related to the initial COVID-19 infection including hospitalization or mechanical ventilation requirement were also collected. The proportion of patients experiencing gastrointestinal symptoms was compared among patients with and without pre-and post-COVID mental health symptoms using Chi square testing. A multivariable logistic regression model was used to identify independent predictors of gastrointestinal symptoms 6 months after COVID diagnosis. J o u r n a l P r e -p r o o f Figure 1B 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation Follow-up of adults with noncritical COVID-19 two months after symptom onset The Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta-Analysis Prevalence and risk factors for gastrointestinal symptoms after recovery from COVID-19 Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders Mood and Anxiety Disorders Precede Development of Functional Gastrointestinal Disorders in Patients but Not in the Population The authors thank Sheila O'Byrne for her assistance with the Columbia University COVID-19 Biobank (CUB) data.